## New pyrrolidon, imidazolon, furanon or thioph non derivatives

Patent Number: DE19626701

Publication

date:

1998-01-08

Inventor(s):

WEHNER VOLKMAR DR (DE); KNOLLE JOCHEN DR (DE); STILZ HANS ULRICH DR

(DE); CARNIATO DENIS DR (FR); GOURVEST JEAN-FRANCOIS DR (FR); GADEK TOM

DR (US); MCDOWELL ROBERT DR (US)

Applicant(s):

HOECHST AG (DE)

Requested

Patent:

☐ <u>DE19626701</u>

Application Number:

ς.

DE19961026701 19960703

Priority Number

(s):

DE19961026701 19960703

IPC Classification:

C07D233/76; C07D403/12; A61K31/47; A61K31/415; A61K31/44; A61K31/425;

on: A61K31/505; C07K5/06; C07D521/00

EC

C07D233/96, C07D403/12, C07D471/10

Classification: Equivalents:

## **Abstract**

5-Membered azacyclic derivatives (I) and their salts are new. W = C(R<16>)-D-B-A-R<1> (a), C=C(R<16>)-D-B-A-R<1> (b) or a group of formula (c) or (d); the ring of formula (e) is saturated or partly or fully unsaturated, and optionally contains 1 or 2 N, O and/or S atoms and is optionally mono-, di- or trisubstituted by R<16> or mono- or disubstituted by =Q; Y = CQ or CH2; Z = N(R<0>), Q or CH2; A = bond, 1-8C alkanediyl, CR<2>=NNR<2>, NR<2>CQNR<2>, QCQ'NR<2>, NR<2>S(O)nNR<2>, OS(O)nNR<2>, S(O) nNR<2>, 3-12 cycloalkanediyl, C?=C, NR<2>CO, CONR<2>, NR<2>CO-5-14C arylene, O, S(O)n, 5-14C arylene, CO, CO-5-14C arylene, NR<2>, NR<2>SO2, OCO, COO, N=CR<2> CR<2>=N, CR<2>=CR<3> or S(O)n-5-14C arylene (all optionally substituted by NR<2> and/or by 1 or 2 1-8C alkanediyl); Q, Q' = O or S; B = bond, 1-8C alkanediyl, 5-10C arylene, 3-8C cycloalkanediyl, C?=C, NR<2>, CO, CONR<2>, NR<2>CO, CONR<2>, NR<2>CONR<2>, NR<2>CO, CONR<2>, NR<2>, NR<2>CO, CONR<2>, NR<2>CO, CONR<2>, NR<2>CO, CONR<2>, NR<2>CO, CONR<2>, NR<2>CO, CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR<2>, NR<2>CONR NR<2>-CQ-NR<2>, OCO, COO, SO, SO2, SONR<2>, SO2NR<2>, NR<2>SO, NR<2>SO2, Q or CR<2>=CR<3> (all optionally mono- or disubstitute d by 1-6C alkanediyl) or a divalent residue of a 5-6 membered saturated or unsaturated ring containing 1 or 2 N atoms (optionally mono- or disubstituted substituted by 1-6C alkyl or =Q); D, F = bond, 1-8C alkanediyl, 5-10C arylene, Q, NR<2>, CONR<2>, NR<2>CO, NR<2>CQNR<2>, OCO, COO, CQ, SO, SO2, SO2NR<2>, NR<2>SO, NR<2>SO2, SO2NR<2>, NR<2>SO2, NR<2 CR<2>=CR<3>, C?=C, CR<2>=NNR<2>, N=CR<2>, CR<2>=N or CHOH (all optionally mono- or disubstituted by 1-8C alkanediyl, CR<2>=CR<3> or 5-6C arylene); E = bond, 1-6C alkanediyl, 2-6C alkenediyl, 2-6C alkynediyl, phenylene, phenylene-1-3C alkanediyl or 1-3C alkanediyl-phenylene; G = CR<4>R<5>(CR<6>R<7>)p(CH2)qR<10>; L = C(R<16>) or N; R<0> = H, 1-8C alkyl (optionally substitutedby 3-12C cycloalkyl or 5-14C aryl), 1-8C alkylcarbonyl, 3-12C cycloalkyl-carbonyl, (3-12C cycloalkyl- or 5-14C aryl-substituted) 1-6C alkylcarbonyl, 5-14C aryl-carbonyl, 3-12C cycloalkyl or 5-14C aryl (where all alkyl are optionally substituted by 1 or more F); R<1> = NR<2>CR<2>(=NR<2>), C(=NR<2>)NR<2>R<3>. NR<2>C(=NR<2>)NR<2>R<3>, or a 4-14 membered mono- or polycyclic optionally aromatic ring (optionally containing 1-4 N, O and/or S and optionally substituted by R<12>-R<15>); R<2>, R<3> = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, 5-14C aryl, 5-14C aryl-1-8C alkyl, NH2; NR<9>OR<8>, R<9>OR<8>, R<9>COOR<8>, R<9>-5-14C aryl-R<8>, R<9>N(R<8>)2, R<9>-NR<8>-(1-8C hydroxyalkyl), R<9>CON(R<8>)2, R<9>NR<8>COR<8>, R<9>COR8, C(=NR<8>)N (R<8>)2; NR<8>C(=NR<8>)N(R<8>)2 or (1-18C alkyl)-COO-1-6C alkoxycarbonyl; R<4>-R<7> = H, F, OH, 1-8C alkyl, 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, R<9>QR<8>, R<9>OCOR<8>, R<9>COOR<8>, R<9>-5-14C aryl-R<8>, R<9>N(R<2>)R<8>, R<9>N(R<8>)2, R<9>OCONR<8>R<2>, R<9>N(R<2>)S(O) nR<8>, R<9>NR<2>COQR<8>, R<9>NR<2>COR<8>, R<9>N(R<2>)CON(R<2>)R<8>, R<9>N(R<2>)S(O)

nNR<2>R<8>, R<9>S(O)nR<8>, R<9>NR<2>COSR<8>, R<9>COR<8>, R<9>CONR<2>R<8> or R<9>S (O)nNR<2>R<8>; R<8> = H, 1-8C alkyl (optionally substituted by 3-12C cycloalkyl or 5-14C aryl), 3-12C cycloalkyl or 5-14C aryl (where all alkyl are optionally substituted by 1 or more F); R<9> = bond or 1-8C alkanediyl; R<10> = CQR<11>, S(O)nR<11>, P(O)nR<11> or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S atoms; R<11> = OH, 1-8C alkoxy, 5-14C aryl-1-8C alkoxy, 5-14C aryl-1-8C alkylcarbonyloxy-1-4C alkoxy, NH2, mono- or di-1-8C alkylamino, 5-14C aryl-1-8C alkylamino, 1-8C dialkylaminocarbonylmethoxy, 5-14C aryl-1-8C dialkylaminocarbonylmethoxy, 5-14C aryl-1-8C dialkylaminocarbonylmethoxy, 5-14C aryl-1-8C alkyl (optionally substituted by one or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, 5-14C aryl-5-14C aryl-1-8C alkyl, NH2, R<9>OR<8>, R<9>COOR<8>, R<9>N(R<8>)2, R<9>-5-14C aryl-R<8>; R<9>-NR<2>(1-8C hydroxyalkyl), R<9>CON(R<2>)R<8>, R<9>N(R<2>)COR<8>, R<9>COR<8>, NR<2>C(=NR<2>)NR<2>C(=NR<2>)NR<2>R<3>, C(=NR<2>)NR<2>R<3> or Q; or 2 of R<12>-R<15> which are adjacent form -OCH2O-, -OCH2CH2O- or -OC(CH3)2O-; R<16> = H, 1-10C alkyl optionally substituted by 1 o

Data supplied from the esp@cenet database - I2



- 19 BUNDESREPUBLIK
  - **DEUTSCHLAND**

## Off nl gungsschrift <sup>®</sup> DE 196 26 701 A 1



**DEUTSCHES PATENTAMT** 

- Aktenzeichen:
- 196 26 701.3
- 2 Anmeldetag:
- 3. 7.98
- Offenlegungstag:
- 8. 1.98

(5) Int. Cl.6:

## C 07 D 233/76

C 07 D 403/12 A 61 K 31/47 A 61 K 31/415 A 61 K 31/44

A 61 K 31/505 C 07 K 5/08 // C07D 521/00

A 61 K 31/425

(C07D 403/12,233:76

249:08)

(7) Anmelder:

Hoechst AG, 65929 Frankfurt, DE

② Erfinder:

Wehner, Volkmar, Dr., 97657 Sandberg, DE; Knolle, Jochen, Dr., 65830 Kriftel, DE; Stilz, Hans Ulrich, Dr., 65929 Frankfurt, DE; Carniato, Denis, Dr., Marcoussis, FR; Gourvest, Jean-Francois, Dr., Claye Souilly, FR; Gadek, Tom, Dr., Oakland, Ca., US; McDowell, Robert, Dr., San Francisco, Ca., US

- Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
- Gegenstand der vorliegenden Erfindung sind 5-Ring-Heterocyclen der allgemeinen Formel I,

in der E, F, G, W, Y und Z die in den Patentansprüchen angegebenen Bedeutungen besitzen, ihre Herstellung, ihre Verwendung als Heilmittel und sie enthaltende pharmazeutische Zubereitungen. Die Verbindungen der Formel I wirken insbesondere als Vitronectinrezeptor-Antagonisten und Inhibitoren der Knochenresorption durch Osteoclasten.